May 2026 in Review: Updates on the Psychiatric Treatment Pipeline

Take a look at this month’s developments in the psychiatric treatment pipeline. We compiled a recap of the latest news here, just in case you missed any of the updates.

Lumateperone Ranks Highest Among Adjunctive MDD Therapies in First Network Meta-Analysis

Johnson & Johnson announced findings from the first network meta-analysis (NMA) comparing lumateperone (Caplyta) with other FDA-approved atypical antipsychotics used as add-on treatment for adults with major depressive disorder (MDD). Presented as a late-breaking poster at the 2026 Neuroscience Education Institute Spring Congress in Kissimmee, Florida, the analysis found lumateperone ranked highest across 4 key efficacy measures and demonstrated a favorable tolerability profile, particularly with respect to weight, when compared with the other agents evaluated. The new analysis ranked lumateperone the best for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.

FDA Clears Clinical Trial of NRX-101 in Combination with Robotic-Enabled TMS in Patients With Depression and Suicidality

The FDA cleared NRx Pharmaceuticals to initiate a clinical trial of NRX-101 (D-cycloserine/lurasidone fixed dose combination) vs placebo in patients with depression and suicidality who are being treated with either robotic-assisted transcranial magnetic stimulation (TMS) or sham TMS. The placebo-controlled phase 2/3 trial is identified as “A Randomized, Double-Blind, Three-Arm Study of NRX-101 as Adjunctive Therapy to Active or Sham Transcranial Magnetic Stimulation in Adults with Treatment Resistant Major Depressive Disorder (MIND1).” Preliminary research suggests that D-cycloserine significantly enhances the effect of TMS, with a greater than 2-fold benefit of reduction in symptoms of depression.

Phase 2 MINDFul Trial Results on XPro1595 for Early Alzheimer Disease With Inflammation

INmune Bio announced that results from its phase 2 MINDFuL trial that evaluated the safety, biomarker engagement, and clinical efficacy of XPro (XPro1595, pegipanermin) in patients with mild Alzheimer disease (AD) characterized by biomarkers of inflammation. In a prespecified analysis of the protocol-defined AD with inflammation subgroup, XPro showed directionally consistent benefit across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks, with no amyloid-related imaging abnormalities observed. However, XPro1595 did not show statistical significance on the primary endpoint within the overall study population.

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

Synendos Therapeutics announced it has started dosing in its phase 2 efficacy and safety clinical trial of SYT-510 in patients with the diagnosis of generalized anxiety disorder (GAD). The trial will investigate the efficacy, safety, tolerability and pharmacokinetics of a single dose of SYT-510 in participants meeting DSM-5 diagnostic criteria for GAD. SYT-510 belongs to a novel class of endocannabinoid system (ECS) modulators called selective endocannabinoid reuptake inhibitors (SERIs), which represent first-in-class, new chemical entities that modulate the ECS through a self-limiting mode of action. This study marks the first time a SERI molecule will be dosed in a patient population.

GLP-1s For Treatment of Alcohol Use Disorder: Current and Future Directions

GLP-1 agents appear to attenuate the wanting, craving, and pleasure experience associated with both food and substances of abuse, potentially interrupting core reinforcement cycles that drive compulsive use. While clinical evidence continues to accumulate, the convergence of mechanistic plausibility, epidemiologic signal, and futures of trial data frames GLP-1 receptor agonists with potential in addiction pharmacotherapy.

Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting

Compass Pathways shared late-breaking poster data at the 2026 ASCP Annual Meeting in Miami, FL, on their phase 3 program investigating COMP360 psilocybin for treatment-resistant depression. Study COMP005 compared a 25 mg dose with a placebo over 26 weeks and 2 doses (1, 10, or 25 mg) against each other. Both studies COMP005 and COMP006 showed highly statistically and clinically significant results, with significant improvements in the Montgomery-Åsberg Depression Rating Scale score. The cohort included patients with severe depression and many lifetime depressive episodes and chronic current episodes. Investigators also noted that 2 treatments were generally better than 1, and that some patients benefited dramatically from a single treatment. These studies aimed to address skepticism by recruiting a valid population without prior psychedelic use and by conducting rigorous, large-scale trials.

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

The FDA has granted de novo approval to Neurovalens’ Modius Spero, a neuromodulation device to treat symptoms associated with posttraumatic stress disorder (PTSD). This is the first neuromodulation device to receive FDA authorization to treat symptoms associated with PTSD. The device uses low-level electrical stimulation to target specific areas of the brain to address the symptoms of PTSD. The FDA’s de novo classification is a pathway designed for new medical devices that have been proven safe and effective for their intended use through clinical testing.

Be sure to follow us on LinkedIn, Facebook, or X, or subscribe to our eNewsletters to stay up to date with the latest news.